OPINION OF THE COURT

This appeal by Chester Brame presents two issues for decision: whether the District Court for the Eastern District of Pennsylvania erred in: (1) interpreting the United States Sentencing Guidelines; and (2) failing to apply the teachings of Blakely v. Washington, 542 U.S. 296, 124 S.Ct. 2531, 159 L.Ed.2d 403 (2004) as refined by United States v. Booker, 543 U.S. -, 125 S.Ct. 738, 160 L.Ed.2d 621 (2005). We will vacate the sentence and remand for resentencing.

I.

Because we write only for the parties, who are familiar with the facts, procedural history and contentions presented, we will not recite them except as necessary to the discussion.

II.

Brame sold to an undercover agent approximately 39 oxycodone tablets. Over the next few weeks, Brame made three additional oxycodone sales of increasing volumes to the agent. Finally, on May 15, 2003, Brame was arrested when he arrived to make a fifth sale to the agent, and almost 600 tablets containing oxycodone were recovered from Brame’s automobile. Brame pleaded guilty to four counts of distribution and one count of possession with intent to distribute tablets containing oxycodone.

Some of the oxycodone tablets involved in the transactions described above were identified by the brand name “OxyContin;” the rest were either “Percocet,” “Roxicet,” or “Endocet.” Brame distributed a total of 844 Percocet tablets and 286 OxyContin tablets. The total weight and amount of oxycodone for each tablet is significant because the 2002 and 2003 editions of the Sentencing Guidelines utilize different methods to calculate drug quantity for oxycodone. The 2003 Guidelines changed the calculation that was previously based on the total weight of a tablet containing oxycodone.

Prior to sentencing, Brame filed a motion for downward departure on the basis that “Percocet (oxycodone), a Schedule II drug, should be treated as a Schedule III drug, such as hydrocodone.” He argued that because hydrocodone and oxycodone *475 were chemically similar, Percocet (which contains less than 15 mg of oxycodone, specifically, 5 mg) should likewise be treated as a Schedule III substance. Brame asserted that this would reduce his offense level to 18 under the 2002 Guidelines.

Nevertheless, at his sentencing hearing, Brame asked the District Court to consider his downward departure motion while applying the 2003 Guidelines. Accepting this invitation, the District Court thereafter declined Brame’s request to treat Percocet in the same manner as hydrocodone, concluding that the Sentencing Commission had adequately considered the treatment of Percocet. Brame’s motion for a downward departure was denied and the Court sentenced him to 57 months imprisonment, the bottom of the applicable guideline range of 57 to 71 months.

The foregoing indicates that the only issues before us call for a review of the District Court’s interpretation of the Sentencing Guidelines. In essence, Appellant has challenged his sentence under United States v. Booker, 543 U.S. -, 125 S.Ct. 738, 160 L.Ed.2d 621 (2005). Having determined that the sentencing issues Brame raises are best determined by the District Court in the first instance, we will vacate the sentence and remand for re-sentencing in accordance with Booker.